secukinumab intravenous infusion — Medica

Initial criteria

• age ≥ 18 years
• prescribed by or in consultation with a rheumatologist or a dermatologist

Reauthorization criteria

• patient established on Cosentyx intravenous or subcutaneous for ≥ 6 months
• When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR compared with baseline, patient experienced an improvement in at least one symptom such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths

Approval duration

initial: 6 months; reauth: 1 year